10 Jun 2025 • Dose-sparing inactivated polio vaccine (ds-IPV) could be a viable, cost-efficient alternative to the standard IPV for infant immunisation.

Key Findings:

• The trial demonstrated high and comparable seroconversion rates for poliovirus types 1, 2, and 3—96%, 95%, and 97% in the ds-IPV group vs. 97%, 98%, and 98% in the full-dose IPV group, respectively.
• Safety profiles were also similar, with solicited adverse events reported in 56% (ds-IPV) and 54% (IPV), and serious adverse events in 3% and 2%, respectively, none linked to the vaccines.

These findings support ds-IPV as an immunologically robust and safe alternative that could ease supply and cost pressures in global polio eradication efforts.

Source: The Lancet | Read Full Story